Genetic Predisposition in Cerebral Palsy (PREGENE PC)
Primary Purpose
Cerebral Palsy
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Whole-exome sequencing
Sponsored by
About this trial
This is an interventional screening trial for Cerebral Palsy focused on measuring Cerebral Palsy, Genetic predisposition, Neurodevelopmental disorder
Eligibility Criteria
Inclusion Criteria:
- Child between 2 and 15 years old with a clinical diagnostic of cerebral paralysis with bilateral somatic involvement
- Child born from 34 SA
- Agreement of the legal representatives for the genetic study
- Both parents available for a parental genetic study (if detection of class 3 variant)
- Affiliation to the social security system
Exclusion Criteria:
- Genetic syndrome identified or malformative or infectious etiologies identified
- Neonatal encephalopathy criteria in a clear obstetrical etiological context responsible for major perinatal anoxia with Sarnat 2 or 3
- Unilateral motor disorders in the term child (congenital hemiplegia)
Sites / Locations
- Service de Médecine Physique et Réadaptation Pédiatrique - Hôpital Femme-Mère-EnfantRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
children with cerebral palsy
Arm Description
Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
Outcomes
Primary Outcome Measures
Proportion of patients for whom a significant genetic variant was identified on the exome by the High-throughput sequencing technique after comparison with the databases of human polymorphisms and pathogenic variants up to date during the analysis.
Are considered positive for a significant genetic variant, patients for whom a or several class 4 or 5 variants have been identified, and explain the phenotype of pc. Genetic variants will be classified according to the recommendations of the American College of Genetics Medical (ACMG: American College of Medical Genetics) from 1 to 5.
Secondary Outcome Measures
Full Information
NCT ID
NCT05317234
First Posted
March 22, 2022
Last Updated
September 8, 2023
Sponsor
Hospices Civils de Lyon
1. Study Identification
Unique Protocol Identification Number
NCT05317234
Brief Title
Genetic Predisposition in Cerebral Palsy
Acronym
PREGENE PC
Official Title
Genetic Predisposition in Cerebral Palsy
Study Type
Interventional
2. Study Status
Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 8, 2023 (Actual)
Primary Completion Date
March 8, 2028 (Anticipated)
Study Completion Date
March 8, 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospices Civils de Lyon
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cerebral palsy (CP) is a major neurodevelopmental disorder with an estimated prevalence of approximately one in 500 children. It is characterised by permanent developmental disorders of movement and posture, responsible for activity limitations, caused by non-progressive damage to the brain of the fetus, newborn or infant during development. The neurobiological mechanisms involved in CP remain poorly understood, although the interruption of cerebral oxygen supply during pregnancy or at the time of delivery is classically considered to be the main factor causing neurodevelopmental sequelae. CP also occurs in full-term infants without a clearly identifiable etiology.
Data from the literature suggest the existence of other pathophysiological processes than only acquired brain lesions related to pregnancy and delivery, such as genetic or epigenetic factors. According to some research teams, nearly one third of CP could have a genetic cause or could be favoured by genetic variants.
Preliminary research has made significant progress in revealing unusual copy number variants and/or mutations in single genes in children with CP. Several of the identified genes are involved in neurodevelopment and neuronal connectivity. Nevertheless, the identification of these abnormalities in CP may contribute to a better understanding of the pathophysiology of this complex and multifactorial disorder. It could also shed new light on the analysis of medico-legal files and bring encouraging perspectives by targeting new therapeutic interventions.
The main hypothesis is that a certain number of cerebral palsies are related to - or favoured by - genetic abnormalities that we will search for with genetic screening tests.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Palsy
Keywords
Cerebral Palsy, Genetic predisposition, Neurodevelopmental disorder
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
Masking
None (Open Label)
Allocation
N/A
Enrollment
250 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
children with cerebral palsy
Arm Type
Experimental
Arm Description
Patients between 2 and 15 years old, born after 34 weeks' gestation, with a diagnosis of cerebral palsy.
Intervention Type
Genetic
Intervention Name(s)
Whole-exome sequencing
Intervention Description
The whole-exome sequencing will be performed via a blood sample from a patient with a diagnosis of cerebral palsy.
Primary Outcome Measure Information:
Title
Proportion of patients for whom a significant genetic variant was identified on the exome by the High-throughput sequencing technique after comparison with the databases of human polymorphisms and pathogenic variants up to date during the analysis.
Description
Are considered positive for a significant genetic variant, patients for whom a or several class 4 or 5 variants have been identified, and explain the phenotype of pc. Genetic variants will be classified according to the recommendations of the American College of Genetics Medical (ACMG: American College of Medical Genetics) from 1 to 5.
Time Frame
Until the end of study, an average of 4.5 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Child between 2 and 15 years old with a clinical diagnostic of cerebral paralysis with bilateral somatic involvement
Child born from 34 SA
Agreement of the legal representatives for the genetic study
Both parents available for a parental genetic study (if detection of class 3 variant)
Affiliation to the social security system
Exclusion Criteria:
Genetic syndrome identified or malformative or infectious etiologies identified
Neonatal encephalopathy criteria in a clear obstetrical etiological context responsible for major perinatal anoxia with Sarnat 2 or 3
Unilateral motor disorders in the term child (congenital hemiplegia)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cyril Huissoud, Pr
Phone
+33427856565
Email
Cyril.huissoud@chu-lyon.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Fanny Joubert
Phone
+33426732727
Email
Fanny.joubert@chu-lyon.fr
Facility Information:
Facility Name
Service de Médecine Physique et Réadaptation Pédiatrique - Hôpital Femme-Mère-Enfant
City
Bron
ZIP/Postal Code
69677
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carole VUILLEROT, MD
Phone
+33 4 72 12 94 50
Email
carole.vuillerot@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Valérie LAUDY, CRA
Phone
+33 4 72 35 75 51
Email
valerie.laudy@chu-lyon.fr
12. IPD Sharing Statement
Learn more about this trial
Genetic Predisposition in Cerebral Palsy
We'll reach out to this number within 24 hrs